MajesTEC-3: Redefining what's possible in multiple myeloma - PubMed
6 hours ago
- #teclistamab
- #MajesTEC-3
- #multiple myeloma
- MajesTEC-3 is a study focusing on advancements in multiple myeloma treatment.
- Key treatments discussed include daratumumab and teclistamab.
- Conflicts of interest noted with consulting fees from Janssen, Sanofi, Legend Biotech, Bristol-Myers Squibb, Arcellx, and Guidepoint.
- References include studies on long-term follow-up of multiple myeloma patients, teclistamab plus daratumumab efficacy, IVIG supplementation effects, infection risks with bispecific antibodies, and nonrelapse mortality post CAR T cell therapy.